GSK’s Shingrix Receives NMPA’s Approval for the Prevention of Shingles in China

 GSK’s Shingrix Receives NMPA’s Approval for the Prevention of Shingles in China

GSK’s Shingrix Receives NMPA’s Approval for the Prevention of Shingles in China

Shots:

  • The approval follows P-III ZOE-50 and ZOE-70 studies assessing Shingrix in 38,000 patients with shingles (herpes zoster) aged ≥ 50yrs.
  • The P-III ZOE-50 and ZOE-70 studies demonstrated efficacy >90% in all age group and showed sustained efficacy over a follow period of 4yrs.
  • Shingrix (IM) is a herpes zoster vaccine, administered in two doses and is a combination of an antigen, glycoprotein E, an adjuvant system, AS01B, currently available in the US, EU, Canada, Japan and Australia

Click here to read full press release/ article | Ref: GSK | Image: CNBC

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post